[The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Lichinitser
M R
MR
Vyshinskaia
G V
GV
Min'kov
E D
ED
Nakhalova
T A
TA
Odzharova
A A
AA
Garin
A M
AM
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D009202:Cardiomyopathies / Q000139:chemically induced / Q000517:prevention & control; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D004347:Drug Interactions; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011929:Razoxane / Q000627:therapeutic use*; D012074:Remission Induction
D002317:Cardiovascular Agents; D011929:Razoxane; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil
Primenenie kardioksana v kachestve kardioprotektornogo sredstva pri protivoopukholevoĭ khimioterapii.